Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and staphylococcus aureus, which is in Phase 3 clinical trial. In addition, it engages in technology promotion and application services business; biotechnology, R&D, and consulting. The company was founded in 2009 and is based in Chengdu, China.
Metrics to compare | 688319 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688319PeersSector | |
---|---|---|---|---|
P/E Ratio | 168.9x | −22.3x | −0.7x | |
PEG Ratio | 0.65 | −0.06 | 0.00 | |
Price/Book | 11.3x | 2.7x | 2.6x | |
Price / LTM Sales | 15.6x | 6.2x | 3.4x | |
Upside (Analyst Target) | 6.9% | 10.5% | 37.9% | |
Fair Value Upside | Unlock | 0.8% | 5.2% | Unlock |